Pulmonary arterial hypertension – progress in understanding the disease and prioritizing strategies for drug development

Journal of Internal Medicine

Volumn 282, Issue 2, 2017, Pages 129-141

  Ghataorhe, P ^a   Rhodes, C J ^a   Harbaum, L ^a   Attard, M ^a   Wharton, J ^a   Wilkins, M R ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

drug development; genetics; metabolome; pathophysiology; personalized medicine; pulmonary hypertension

Indexed keywords

BIOLOGICAL MARKER; BONE MORPHOGENETIC PROTEIN RECEPTOR 2; GROWTH FACTOR; POTASSIUM CHANNEL; POTASSIUM CHANNEL KCNK3; UNCLASSIFIED DRUG;

DEMOGRAPHY; DRUG DEVELOPMENT; GENE MUTATION; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; HEART RIGHT VENTRICLE; HUMAN; INFLAMMATION; LUNG BLOOD VESSEL; LUNG CIRCULATION; METABOLISM; MOLECULAR PATHOLOGY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; BLOOD; CLASSIFICATION; GENETIC PREDISPOSITION; HEART RIGHT VENTRICLE FUNCTION; HEMODYNAMICS; HYPERTENSION, PULMONARY;

BIOMARKERS; GENETIC PREDISPOSITION TO DISEASE; HEMODYNAMICS; HUMANS; HYPERTENSION, PULMONARY; VENTRICULAR FUNCTION, RIGHT;

EID: 85019365988     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/joim.12623     Document Type: Review

References (130)

1. Hoeper MM, Humbert M, Souza R et al. A global view of pulmonary hypertension. Lancet Respirat Med 2016; 4: 306–22.
2. Hoeper MM, Bogaard HJ, Condliffe R et al. Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol 2013a; 62: D42–50.
3. Maron BA, Hess E, Maddox TM et al. Association of borderline pulmonary hypertension with mortality and hospitalization in a large patient cohort: insights from the veterans affairs clinical assessment, reporting, and tracking program. Circulation 2016; 133: 1240–8.
4. Aronson D, Eitan A, Dragu R, Burger AJ. Relationship between reactive pulmonary hypertension and mortality in patients with acute decompensated heart failure. Circ Heart Fail 2011; 4: 644–50.
5. Maron BA, Abman SH. Focusing on developmental origins and disease inception for the prevention of pulmonary hypertension. Am J Respir Crit Care Med 2016; 195: 292–301.
6. Galie N, Humbert M, Vachiery JL et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J 2015a; 46: 903–75.
7. Dweik RA, Rounds S, Erzurum SC et al., An official American Thoracic Society Statement: pulmonary hypertension phenotypes. Am J Respir Crit Care Med 2014; 189: 345–55.
8. McGoon MD, Benza RL, Escribano-Subias P et al. Pulmonary arterial hypertension: epidemiology and registries. J Am Coll Cardiol 2013; 62: D51–9.
9. Ling Y, Johnson MK, Kiely DG et al. Changing demographics, epidemiology, and survival of incident pulmonary arterial hypertension: results from the pulmonary hypertension registry of the United Kingdom and Ireland. Am J Respir Crit Care Med 2012; 186: 790–6.
10. Farber HW, Miller DP, Poms AD et al. Five-Year outcomes of patients enrolled in the REVEAL Registry. Chest 2015; 148: 1043–54.
11. Badesch DB, Raskob GE, Elliott CG et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest 2010; 137: 376–87.
12. Evans JD, Girerd B, Montani D et al. BMPR2 mutations and survival in pulmonary arterial hypertension: an individual participant data meta-analysis. Lancet Respir Med 2016; 4: 129–37.
13. Rich S, Dantzker DR, Ayres SM et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med 1987; 107: 216–23.
14. Hoeper MM, Huscher D, Ghofrani HA et al. Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: results from the COMPERA registry. Int J Cardiol 2013b; 168: 871–80.
15. Opitz CF, Hoeper MM, Gibbs JS et al. Pre-capillary, combined, and post-capillary pulmonary hypertension: a pathophysiological continuum. J Am Coll Cardiol 2016; 68: 368–78.
16. Leopold JA. Biological phenotyping of combined post-capillary and pre-capillary pulmonary hypertension: focus on pulmonary vascular remodeling. J Am Coll Cardiol 2016; 68: 2537–9.
17. Chen Y, Guo H, Xu D et al. Left ventricular failure produces profound lung remodeling and pulmonary hypertension in mice: heart failure causes severe lung disease. Hypertension 2012; 59: 1170–8.
18. Tuder RM. Pulmonary vascular remodeling in pulmonary hypertension. Cell Tissue Res 2017; 367: 643–649.
19. Tuder RM, Stacher E, Robinson J, Kumar R, Graham BB. Pathology of pulmonary hypertension. Clin Chest Med 2013; 34: 639–50.
20. Stacher E, Graham BB, Hunt JM et al. Modern age pathology of pulmonary arterial hypertension. Am J Respir Crit Care Med 2012; 186: 261–72.
21. Ranchoux B, Antigny F, Rucker-Martin C et al. Endothelial-to-mesenchymal transition in pulmonary hypertension. Circulation 2015; 131: 1006–18.
22. Hopper RK, Moonen JR, Diebold I et al. In pulmonary arterial hypertension, reduced BMPR2 promotes endothelial-to-mesenchymal transition via HMGA1 and its target slug. Circulation 2016; 133: 1783–94.
23. Stenmark KR, Frid M, Perros F. Endothelial-to-mesenchymal transition: an evolving paradigm and a promising therapeutic target in PAH. Circulation 2016; 133: 1734–7.
24. Machado RD, Eickelberg O, Elliott CG et al. Genetics and genomics of pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54: S32–42.
25. Soubrier F, Chung WK, Machado R et al. Genetics and genomics of pulmonary arterial hypertension. J Am Coll Cardiol 2013; 62: D13–21.
26. van de Veerdonk MC, Kind T, Marcus JT et al. Progressive right ventricular dysfunction in patients with pulmonary arterial hypertension responding to therapy. J Am Coll Cardiol 2011; 58: 2511–9.
27. Voelkel NF, Cool C, Lee SD, Wright L, Geraci MW, Tuder RM. Primary pulmonary hypertension between inflammation and cancer. Chest 1998; 114: 225S–30S.
28. Rai PR, Cool CD, King JA et al. The cancer paradigm of severe pulmonary arterial hypertension. Am J Respir Crit Care Med 2008; 178: 558–64.
29. Pullamsetti SS, Savai R, Seeger W, Goncharova EA. Translational advances in the field of pulmonary hypertension. from cancer biology to new pulmonary arterial hypertension therapeutics. targeting cell growth and proliferation signaling hubs. Am J Respir Crit Care Med 2017; 195: 425–437.
30. Ghofrani HA, Seeger W, Grimminger F. Imatinib for the treatment of pulmonary arterial hypertension. N Engl J Med 2005; 353: 1412–3.
31. Ghofrani HA, Morrell NW, Hoeper MM et al. Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. Am J Respir Crit Care Med 2010; 182: 1171–7.
32. Humbert M. Impression, sunset. Circulation 2013; 127: 1098–100.
33. Tuder RM, Groves B, Badesch DB, Voelkel NF. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol 1994; 144: 275–85.
34. Rabinovitch M, Guignabert C, Humbert M, Nicolls MR. Inflammation and immunity in the pathogenesis of pulmonary arterial hypertension. Circ Res 2014; 115: 165–75.
35. Perros F, Dorfmuller P, Montani D et al. Pulmonary lymphoid neogenesis in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 2012; 185: 311–21.
36. Paulin R, Michelakis ED. The metabolic theory of pulmonary arterial hypertension. Circ Res 2014; 115: 148–64.
37. Sutendra G, Michelakis ED. The metabolic basis of pulmonary arterial hypertension. Cell Metab 2014; 19: 558–73.
38. Sutendra G, Michelakis ED. Pulmonary arterial hypertension: challenges in translational research and a vision for change. Sci Transl Med 2013; 5: 208sr5.
39. Ryan JJ, Archer SL. Emerging concepts in the molecular basis of pulmonary arterial hypertension: part I: metabolic plasticity and mitochondrial dynamics in the pulmonary circulation and right ventricle in pulmonary arterial hypertension. Circulation 2015; 131: 1691–702.
40. Cottrill KA, Chan SY. Metabolic dysfunction in pulmonary hypertension: the expanding relevance of the Warburg effect. Eur J Clin Invest 2013; 43: 855–65.
41. Archer SL, Fang YH, Ryan JJ, Piao L. Metabolism and bioenergetics in the right ventricle and pulmonary vasculature in pulmonary hypertension. Pulmonary Circulat 2013; 3: 144–52.
42. Zhao Y, Peng J, Lu C et al. Metabolomic heterogeneity of pulmonary arterial hypertension. PLoS ONE 2014; 9: e88727.
43. Zhao YD, Chu L, Lin K et al. A Biochemical approach to understand the pathogenesis of advanced pulmonary arterial hypertension: metabolomic profiles of Arginine, Sphingosine-1-phosphate, and heme of human lung. PLoS ONE 2015; 10: e0134958.
44. Piao L, Sidhu VK, Fang YH et al. FOXO1-mediated upregulation of pyruvate dehydrogenase kinase-4 (PDK4) decreases glucose oxidation and impairs right ventricular function in pulmonary hypertension: therapeutic benefits of dichloroacetate. J Mol Med 2013; 91: 333–46.
45. Guignabert C, Tu L, Izikki M et al. Dichloroacetate treatment partially regresses established pulmonary hypertension in mice with SM22alpha-targeted overexpression of the serotonin transporter. FASEB J 2009; 23: 4135–47.
46. McMurtry MS, Bonnet S, Wu X et al. Dichloroacetate prevents and reverses pulmonary hypertension by inducing pulmonary artery smooth muscle cell apoptosis. Circ Res 2004; 95: 830–40.
47. Michelakis ED, McMurtry MS, Wu XC et al. Dichloroacetate, a metabolic modulator, prevents and reverses chronic hypoxic pulmonary hypertension in rats: role of increased expression and activity of voltage-gated potassium channels. Circulation 2002; 105: 244–50.
48. Ventetuolo CE, Baird GL, Barr RG et al. Higher estradiol and lower dehydroepiandrosterone-sulfate levels are associated with pulmonary arterial hypertension in men. Am J Respir Crit Care Med 2016; 193: 1168–75.
49. Pullamsetti S, Kiss L, Ghofrani HA et al. Increased levels and reduced catabolism of asymmetric and symmetric dimethylarginines in pulmonary hypertension. FASEB J 2005; 19: 1175–7.
50. Nagaya N, Uematsu M, Oya H et al. Short-term oral administration of L-arginine improves hemodynamics and exercise capacity in patients with precapillary pulmonary hypertension. Am J Respir Crit Care Med 2001; 163: 887–91.
51. Hoet PH, Nemery B. Polyamines in the lung: polyamine uptake and polyamine-linked pathological or toxicological conditions. Am J Physiol: Heart Circul Physiol 2000; 278: L417–33.
52. Olson JW, Atkinson JE, Hacker AD, Altiere RJ, Gillespie MN. Suppression of polyamine biosynthesis prevents monocrotaline-induced pulmonary edema and arterial medial thickening. Toxicol Appl Pharmacol 1985; 81: 91–9.
53. Herve P, Launay JM, Scrobohaci ML et al. Increased plasma serotonin in primary pulmonary hypertension. Am J Med 1995; 99: 249–54.
54. Jasiewicz M, Moniuszko M, Pawlak D et al. Activity of the kynurenine pathway and its interplay with immunity in patients with pulmonary arterial hypertension. Heart 2016; 102: 230–7.
55. Lewis GD, Ngo D, Hemnes AR et al. Metabolic profiling of right ventricular-pulmonary vascular function reveals circulating biomarkers of pulmonary hypertension. J Am Coll Cardiol 2016; 67: 174–89.
56. Chen J, Tang H, Sysol JR et al. The sphingosine kinase 1/sphingosine-1-phosphate pathway in pulmonary arterial hypertension. Am J Respir Crit Care Med 2014; 190: 1032–43.
57. Rhodes CJ, Ghataorhe P, Wharton J et al. Plasma metabolomics implicate modified transfer RNAs and altered bioenergetics in the outcome of pulmonary arterial hypertension. Circulation 2016; 135: 460–75.
58. Brittain EL, Talati M, Fessel JP et al. Fatty acid metabolic defects and right ventricular lipotoxicity in human pulmonary arterial hypertension. Circulation 2016; 133: 1936–44.
59. Deng Z, Morse JH, Slager SL et al. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet 2000; 67: 737–44.
60. International PPHC, Lane KB, Machado RD et al. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. Nat Genet 2000; 26: 81–4.
61. Newman JH, Trembath RC, Morse JA et al. Genetic basis of pulmonary arterial hypertension: current understanding and future directions. J Am Coll Cardiol 2004; 43: 33S–9S.
62. Foletta VC, Lim MA, Soosairajah J et al. Direct signaling by the BMP type II receptor via the cytoskeletal regulator LIMK1. J Cell Biol 2003; 162: 1089–98.
63. Ma L, Chung WK. The genetic basis of pulmonary arterial hypertension. Hum Genet 2014; 133: 471–9.
64. Graf S, Morrell NW. Towards a molecular classification of pulmonary arterial hypertension. Eur Respir J 2016; 48: 987–9.
65. Stearman RS, Cornelius AR, Lu X et al. Functional prostacyclin synthase promoter polymorphisms. Impact in pulmonary arterial hypertension. Am J Respir Crit Care Med 2014; 189: 1110–20.
66. Wang G, Knight L, Ji R et al. Early onset severe pulmonary arterial hypertension with ‘two-hit’ digenic mutations in both BMPR2 and KCNA5 genes. Int J Cardiol 2014; 177: e167–9.
67. Wang H, Li W, Zhang W et al. Novel promoter and exon mutations of the BMPR2 gene in Chinese patients with pulmonary arterial hypertension. Eur J Hum Genet 2009; 17: 1063–9.
68. Aldred MA, Machado RD, James V, Morrell NW, Trembath RC. Characterization of the BMPR2 5′-untranslated region and a novel mutation in pulmonary hypertension. Am J Respir Crit Care Med 2007; 176: 819–24.
69. Viales RR, Eichstaedt CA, Ehlken N et al. Mutation in BMPR2 promoter: a ‘Second Hit’ for manifestation of pulmonary arterial hypertension? PLoS ONE 2015; 10: e0133042.
70. Damico R, Kolb TM, Valera L et al. Serum endostatin is a genetically determined predictor of survival in pulmonary arterial hypertension. Am J Respir Crit Care Med 2015; 191: 208–18.
71. Benza RL, Gomberg-Maitland M, Demarco T et al. Endothelin-1 pathway polymorphisms and outcomes in pulmonary arterial hypertension. Am J Respir Crit Care Med 2015; 192: 1345–54.
72. Austin ED, West J, Loyd JE, Hemnes AR. Translational advances in the field of pulmonary hypertension molecular medicine of pulmonary arterial hypertension. From population genetics to precision medicine and gene editing. Am J Respir Crit Care Med 2017; 195: 23–31.
73. Dawes TJW, de Marvao A, Shi W et al. Machine learning of three-dimensional right ventricular motion enables outcome prediction in pulmonary hypertension: a cardiac MR imaging study. Radiology 2017; 283: 381–390.
74. Voelkel NF, Quaife RA, Leinwand LA et al., Right ventricular function and failure: report of a National Heart, Lung, and Blood Institute working group on cellular and molecular mechanisms of right heart failure. Circulation 2006; 114: 1883–91.
75. Vanderpool RR, Pinsky MR, Naeije R et al. RV-pulmonary arterial coupling predicts outcome in patients referred for pulmonary hypertension. Heart 2015; 101: 37–43.
76. Bogaard HJ, Abe K, Vonk Noordegraaf A, Voelkel NF. The right ventricle under pressure: cellular and molecular mechanisms of right-heart failure in pulmonary hypertension. Chest 2009; 135: 794–804.
77. Voeller RK, Aziz A, Maniar HS et al. Differential modulation of right ventricular strain and right atrial mechanics in mild vs. severe pressure overload. Am J Physiol Heart Circ Physiol 2011; 301: H2362–71.
78. Vonk-Noordegraaf A, Haddad F, Chin KM et al. Right heart adaptation to pulmonary arterial hypertension: physiology and pathobiology. J Am Coll Cardiol 2013; 62: D22–33.
79. Raina A, Humbert M. Risk assessment in pulmonary arterial hypertension. Eur Respir Rev 2016; 25: 390–8.
80. Sitbon O, Humbert M, Nunes H et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002; 40: 780–8.
81. McLaughlin VV, Sitbon O, Badesch DB et al. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J 2005; 25: 244–9.
82. Nickel N, Golpon H, Greer M et al. The prognostic impact of follow-up assessments in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 2012; 39: 589–96.
83. Rich JD, Thenappan T, Freed B et al. QTc prolongation is associated with impaired right ventricular function and predicts mortality in pulmonary hypertension. Int J Cardiol 2013; 167: 669–76.
84. Benza RL, Miller DP, Gomberg-Maitland M et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation 2010; 122: 164–72.
85. Barst RJ, Chung L, Zamanian RT, Turner M, McGoon MD. Functional class improvement and 3-year survival outcomes in patients with pulmonary arterial hypertension in the REVEAL Registry. Chest 2013; 144: 160–8.
86. Savarese G, Paolillo S, Costanzo P et al. Do changes of 6-minute walk distance predict clinical events in patients with pulmonary arterial hypertension? A meta-analysis of 22 randomized trials. J Am Coll Cardiol 2012; 60: 1192–201.
87. Courand PY, Pina Jomir G, Khouatra C et al. Prognostic value of right ventricular ejection fraction in pulmonary arterial hypertension. Eur Respir J 2015; 45: 139–49.
88. Raymond RJ, Hinderliter AL, Willis PW et al. Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension. J Am Coll Cardiol 2002; 39: 1214–9.
89. Badagliacca R, Poscia R, Pezzuto B et al. Right ventricular concentric hypertrophy and clinical worsening in idiopathic pulmonary arterial hypertension. J Heart Lung Transpl 2016; 35: 1321–9.
90. Swift AJ, Rajaram S, Campbell MJ et al. Prognostic value of cardiovascular magnetic resonance imaging measurements corrected for age and sex in idiopathic pulmonary arterial hypertension. Circ Cardiovasc Imaging 2014; 7: 100–6.
91. Fritz JS, Blair C, Oudiz RJ et al. Baseline and follow-up 6-min walk distance and brain natriuretic peptide predict 2-year mortality in pulmonary arterial hypertension. Chest 2013; 143: 315–23.
92. Nagaya N, Nishikimi T, Uematsu M et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 2000; 102: 865–70.
93. Fijalkowska A, Kurzyna M, Torbicki A et al. Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension. Chest 2006; 129: 1313–21.
94. Leuchte HH, Holzapfel M, Baumgartner RA, Neurohr C, Vogeser M, Behr J. Characterization of brain natriuretic peptide in long-term follow-up of pulmonary arterial hypertension. Chest 2005; 128: 2368–74.
95. Shah SJ, Thenappan T, Rich S, Tian L, Archer SL, Gomberg-Maitland M. Association of serum creatinine with abnormal hemodynamics and mortality in pulmonary arterial hypertension. Circulation 2008; 117: 2475–83.
96. Quarck R, Nawrot T, Meyns B, Delcroix M. C-reactive protein: a new predictor of adverse outcome in pulmonary arterial hypertension. J Am Coll Cardiol 2009; 53: 1211–8.
97. Kumpers P, Nickel N, Lukasz A et al. Circulating angiopoietins in idiopathic pulmonary arterial hypertension. Eur Heart J 2010; 31: 2291–300.
98. Takeda Y, Takeda Y, Tomimoto S, Tani T, Narita H, Kimura G. Bilirubin as a prognostic marker in patients with pulmonary arterial hypertension. BMC Pulm Med 2010; 10: 22.
99. Rhodes CJ, Wharton J, Howard LS, Gibbs JS, Wilkins MR. Red cell distribution width outperforms other potential circulating biomarkers in predicting survival in idiopathic pulmonary arterial hypertension. Heart 2011; 97: 1054–60.
100. Cracowski JL. Towards prognostic biomarkers in pulmonary arterial hypertension. Eur Respir J 2012; 39: 799–801.
101. Rhodes CJ, Wharton J, Boon RA et al. Reduced microRNA-150 is associated with poor survival in pulmonary arterial hypertension. Am J Respir Crit Care Med 2013; 187: 294–302.
102. Fenster BE, Lasalvia L, Schroeder JD et al. Cystatin C: a potential biomarker for pulmonary arterial hypertension. Respirology 2014; 19: 583–9.
103. Heresi GA, Aytekin M, Hammel JP, Wang S, Chatterjee S, Dweik RA. Plasma interleukin-6 adds prognostic information in pulmonary arterial hypertension. Eur Respir J 2014; 43: 912–4.
104. Zheng YG, Yang T, He JG et al. Plasma soluble ST2 levels correlate with disease severity and predict clinical worsening in patients with pulmonary arterial hypertension. Clin Cardiol 2014; 37: 365–70.
105. Pezzuto B, Badagliacca R, Poscia R et al. Circulating biomarkers in pulmonary arterial hypertension: update and future direction. J Heart Lung Transpl 2015; 34: 282–305.
106. Bujak R, Mateo J, Blanco I et al. New biochemical insights into the mechanisms of pulmonary arterial hypertension in humans. PLoS ONE 2016; 11: e0160505.
107. Sitbon O, Humbert M, Jais X et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005; 111: 3105–11.
108. McLaughlin VV, Shah SJ, Souza R, Humbert M. Management of pulmonary arterial hypertension. J Am Coll Cardiol 2015; 65: 1976–97.
109. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004; 351: 1425–36.
110. Ghofrani HA, Galie N, Grimminger F et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med 2013; 369: 330–40.
111. Galie N, Barbera JA, Frost AE et al. Initial use of Ambrisentan plus Tadalafil in pulmonary arterial hypertension. N Engl J Med 2015b; 373: 834–44.
112. Sitbon O, Jais X, Savale L et al. Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study. Eur Respir J 2014; 43: 1691–7.
113. Lythgoe MP, Rhodes CJ, Ghataorhe P, Attard M, Wharton J, Wilkins MR. Why drugs fail in clinical trials in pulmonary arterial hypertension, and strategies to succeed in the future. Pharmacol Ther 2016; 164: 195–203.
114. Bonnet S, Provencher S, Guignabert C et al. Translating research into improved patient care in pulmonary arterial hypertension. Am J Respir Crit Care Med 2017; 195: 583–595.
115. Humbert M, Lau EM, Montani D, Jais X, Sitbon O, Simonneau G. Advances in therapeutic interventions for patients with pulmonary arterial hypertension. Circulation 2014; 130: 2189–208.
116. Simonneau G, Hoeper MM, McLaughlin V, Rubin L, Galie N. Future perspectives in pulmonary arterial hypertension. Eur Respir Rev 2016; 25: 381–9.
117. Thompson AA, Lawrie A. Targeting vascular remodeling to treat pulmonary arterial hypertension. Trends Mol Med 2017; 23: 31–45.
118. Chun HJ, Bonnet S, Chan SY. Translational advances in the field of pulmonary hypertension. Translating MicroRNA biology in pulmonary hypertension. It Will Take More Than “miR” Words. Am J Respir Crit Care Med 2017; 195: 167–78.
119. Chambliss AB, Chan DW. Precision medicine: from pharmacogenomics to pharmacoproteomics. Clin Proteomics 2016; 13: 25.
120. Brittain EL, Chan SY. Integration of complex data sources to provide biologic insight into pulmonary vascular disease (2015 Grover Conference Series). Pulmonary Circul 2016; 6: 251–60.
121. Zhang M, Schmitt-Ulms G, Sato C et al.,Drug repositioning for Alzheimer's disease based on systematic ‘omics’ data mining. PLoS ONE 2016; 11: e0168812.
122. Lamb J, Crawford ED, Peck D et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 2006; 313: 1929–35.
123. Wanichthanarak K, Fahrmann JF, Grapov D. Genomic, proteomic, and metabolomic data integration strategies. Biomark Insights 2015; 10: 1–6.
124. Cambiaghi A, Ferrario M, Masseroli M. Analysis of metabolomic data: tools, current strategies and future challenges for omics data integration. Brief Bioinform 2016; pii: bbw031.
125. Lusis AJ, Weiss JN. Cardiovascular networks: systems-based approaches to cardiovascular disease. Circulation 2010; 121: 157–70.
126. Barabasi AL, Gulbahce N, Loscalzo J. Network medicine: a network-based approach to human disease. Nat Rev Genet 2011; 12: 56–68.
127. Vidal M, Cusick ME, Barabasi AL. Interactome networks and human disease. Cell 2011; 144: 986–98.
128. Menche J, Sharma A, Kitsak M et al. Disease networks. Uncovering disease-disease relationships through the incomplete interactome. Science 2015; 347: 1257601.
129. Parikh VN, Jin RC, Rabello S et al. MicroRNA-21 integrates pathogenic signaling to control pulmonary hypertension: results of a network bioinformatics approach. Circulation 2012; 125: 1520–32.
130. Simonneau G, Gatzoulis MA, Adatia I et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2013; 62: D34–41.